InLighta BioSciences L.L.C. was formed in 2014 by
Dr. Jenny J. Yang, to
develop patented protein-based contrast agents for pre-clinical and clinical
Our precision Magnetic Resonance Imaging (pMRI) technology addresses current deficiencies in medical diagnostics for early detection, monitoring disease progression, image-guided intervention, and evaluating drug delivery and therapeutic treatment.
Protein-based Contrast Agents (ProCAs) combined with pMRI technologies, provide significantly improved sensitivity and accuracy for assessing a broad range of diseases including cancers and fibrosis, and effective molecular MR imaging of multiple biomarkers for breast, lung, ovarian, prostate cancer and liver metastases from uveal melanoma, breast and ovarian cancer.
MRI Contrast Agents
InLighta is currently developing high-contrast agents for MR imaging. The ProCA series of contrast agents includes both blood pool agents and targeted contrast agents for specific biomarkers.
The ProCA series
1. Blood Pool Agents
2. Targeted Contrast Agents